CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.75B, above the global median of $1.18B
- FinancialsHigh structural barrier to entry
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.75BUSDvs all stocks (USD)
Revenue (TTM)
413.80MUSDvs all stocks (USD)
Profit Margin
-59.87%vs Biotechnology peers
Beta
2.45xvs all stocks
52-Week Change
24.04%vs all stocks
Market Capitalization
1.75BUSDvs all stocks (USD)
Enterprise Value
1.33BUSDvs all stocks (USD)
Forward P/E
-17.32xvs Biotechnology peers
Price to Sales (TTM)
4.24xvs Biotechnology peers
Enterprise to Revenue
3.22xvs Biotechnology peers
Enterprise to EBITDA
-13.11xvs Biotechnology peers
Gross Margin
74.87%vs Biotechnology peers
Profit Margin
-59.87%vs Biotechnology peers
Operating Margin
-89.61%vs Biotechnology peers
Return on Assets (TTM)
-6.51%vs Biotechnology peers
Revenue (TTM)
413.80MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.54USDUpdated Sep 28, 2026Quarterly Revenue Growth
-76.30%vs Biotechnology peers
Gross Profit (TTM)
-10.58MUSDvs all stocks (USD)
EBITDA (TTM)
618.89MUSDvs all stocks (USD)
Net Income (TTM)
-247.73MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-76.30%vs Biotechnology peers
Operating Cash Flow (TTM)
-36.90MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.12BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
73.04MUSDFY2025 · Dec 31, 2025Gross Profit
1.05BUSDFY2025 · Dec 31, 2025Operating Income
550.64MUSDvs all stocks (USD)
Pre-tax Income
442.17MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.86MUSDFY2025 · Dec 31, 2025Net Income
440.30MUSDFY2025 · Dec 31, 2025EBIT
464.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
618.89MUSDFY2025 · Dec 31, 2025Research & Development
342.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
157.48MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
22.55MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.72USDFY2025 · Dec 31, 2025EPS (Diluted)
2.58USDFY2025 · Dec 31, 2025Basic Shares Outstanding
161.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
161.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
440.30MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-378.02MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
256.05MUSDFY2025 · Dec 31, 2025Income Tax Paid
8.81MUSDFY2025 · Dec 31, 2025Interest Paid
15.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
440.30MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
27.61MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.02MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.76MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
61.04MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-322.57MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-626.18MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-828.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-445.27MUSDFY2025 · Dec 31, 2025Sale of Investments
353.74MUSDFY2025 · Dec 31, 2025Other Investing Activity
19.65MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-71.88MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
42.61MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-10.07MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
32.53MUSDFY2025 · Dec 31, 2025Shares Outstanding
164.82MSharesUpdated Sep 28, 2026Float Shares
142.52MSharesUpdated Sep 28, 2026Shares Short
49.88MSharesUpdated Sep 28, 2026Short Ratio
8.93daysvs all stocks
Short % of Shares Outstanding
30.43%vs all stocks
% Held by Insiders
5.08%vs all stocks
% Held by Institutions
68.68%vs all stocks
Total Cash (MRQ)
719.34MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.36USDUpdated Sep 28, 2026Total Debt (MRQ)
297.32MUSDvs all stocks (USD)
Current Ratio (MRQ)
2.33xvs Biotechnology peers
Book Value per Share (MRQ)
-1.16USDUpdated Sep 28, 2026Total Assets
1.18BUSDvs all stocks (USD)
Total Current Assets
978.28MUSDFY2025 · Dec 31, 2025Total Liabilities
1.30BUSDFY2025 · Dec 31, 2025Total Non-current Assets
198.24MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
844.32MUSDFY2025 · Dec 31, 2025Total Current Liabilities
459.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
240.63MUSDFY2025 · Dec 31, 2025Other Short-term Investments
494.45MUSDFY2025 · Dec 31, 2025Accounts Receivable
106.45MUSDFY2025 · Dec 31, 2025Inventory
11.54MUSDFY2025 · Dec 31, 2025Accounts Payable
24.58MUSDFY2025 · Dec 31, 2025Short-term Debt
2.51MUSDFY2025 · Dec 31, 2025Deferred Revenue
140.05MUSDFY2025 · Dec 31, 2025Other Current Liabilities
185.65MUSDFY2025 · Dec 31, 2025Long-term Debt
246.30MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
239.07MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.65MUSDFY2025 · Dec 31, 2025Retained Earnings
-4.57BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-127.75MUSDvs all stocks (USD)
Treasury Stock
103.02MUSDFY2025 · Dec 31, 202552-Week Low
6.20USDUpdated Sep 28, 202652-Week High
11.97USDUpdated Sep 28, 202652-Week Change
24.04%vs all stocks
Beta
2.45xvs all stocks
50-Day MA
8.78USDUpdated Sep 28, 2026200-Day MA
8.77USDUpdated Sep 28, 2026Avg 10-Day Volume
5.73MSharesUpdated Sep 28, 2026Avg 30-Day Volume
5.67MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.53USDUpdated Sep 28, 2026Other Income / Expense
-85.93MUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.75Profit Margin: -0.60
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 6.38
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.75B, above the global median of $1.18BNotable
Market cap (USD): 1,753,373,067Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
5 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsOperating Income Growing With Multi-Year Revenue GrowthLow Fixed-Asset Share With Elevated TurnoverThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Lundin Gold Inc
5 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsOperating Income Growing With Multi-Year Revenue GrowthLow Fixed-Asset Share With Elevated TurnoverThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Ubiquiti Inc.
4 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsLow Fixed-Asset Share With Elevated TurnoverThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated